# **House of Representatives**



General Assembly

File No. 82

January Session, 2013

House Bill No. 6389

House of Representatives, March 20, 2013

The Committee on Public Health reported through REP. JOHNSON of the 49th Dist., Chairperson of the Committee on the part of the House, that the bill ought to pass.

#### AN ACT CONCERNING PRESCRIPTION DRUG MONITORING.

Be it enacted by the Senate and House of Representatives in General Assembly convened:

- 1 Section 1. Section 21a-317 of the general statutes is repealed and the
- 2 following is substituted in lieu thereof (*Effective October 1, 2013*):
- 3 Every practitioner who distributes, administers or dispenses any
- 4 controlled substance or who proposes to engage in distributing,
- 5 prescribing, administering or dispensing any controlled substance
- 6 within this state shall (1) obtain a certificate of registration issued by
- 7 the Commissioner of Consumer Protection in accordance with the
- 8 provisions of this chapter, and (2) register for access to the electronic
- 9 prescription drug monitoring program, established in accordance with
- 10 subjection (j) of section 21a-254, in the manner prescribed by the
- 11 commissioner.

This act shall take effect as follows and shall amend the following sections:

Section 1	October 1, 2013	21a-317
occuon 1	0000001 1/ 2010	<b>_1</b> u 017

PH Joint Favorable

The following Fiscal Impact Statement and Bill Analysis are prepared for the benefit of the members of the General Assembly, solely for purposes of information, summarization and explanation and do not represent the intent of the General Assembly or either chamber thereof for any purpose. In general, fiscal impacts are based upon a variety of informational sources, including the analyst's professional knowledge. Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.

# **OFA Fiscal Note**

State Impact: None

Municipal Impact: None

Explanation

There is no fiscal impact to the Department of Consumer Protection by requiring every practitioner who distributes, administers or dispenses any controlled substance or who proposes to engage in distributing, prescribing, administering or dispensing any controlled substance within this state to register for access to the electronic prescription drug monitoring program as the registration system already exists and there is no fee for registration.

# The Out Years

None

# OLR Bill Analysis HB 6389

# AN ACT CONCERNING PRESCRIPTION DRUG MONITORING.

#### **SUMMARY:**

This bill requires people or institutions that must register with the Department of Consumer Protection (DCP) as controlled substance practitioners to also register for access to DCP's electronic prescription drug monitoring program. They must do so in the manner the DCP commissioner prescribes. By law, the program allows practitioners to see a patient's complete prescription record, including prescriptions by other providers (see BACKGROUND).

The bill applies to practitioners distributing; administering; dispensing; or proposing to distribute, prescribe, administer, or dispense controlled substances in Connecticut. By law, such practitioners must register with DCP as controlled substance practitioners.

For this purpose, practitioners are: physicians; dentists; veterinarians; podiatrists; optometrists; physician assistants; advanced practice registered nurses; nurse-midwives; scientific investigators; hospitals; or other people or institutions licensed, registered, or otherwise permitted to distribute, dispense, conduct research with respect to, or administer a controlled substance in the course of professional practice or research in the state.

EFFECTIVE DATE: October 1, 2013

# **BACKGROUND**

# Prescription Drug Monitoring Program

DCP's electronic prescription drug monitoring program collects and maintains in a central database prescription data for Schedule II

through Schedule V controlled substances dispensed by pharmacies and outpatient pharmacies in hospitals or institutions. Information in the database is available to prescribing practitioners and pharmacists in the treatment of their patients. The program is intended to prevent the improper or illegal use of controlled substances.

#### Related Bills

HB 6406, reported favorably by the General Law Committee, also requires controlled substance practitioners to register for access to the prescription drug monitoring program and makes other changes to the program.

HB 5906, reported favorably by the General Law Committee, requires controlled substance practitioners, before distributing, prescribing, administering, or dispensing a controlled substance, to review the prescription drug monitoring program for the patient's previous history of controlled substance use.

#### **COMMITTEE ACTION**

Public Health Committee

```
Joint Favorable
Yea 28 Nay 0 (03/11/2013)
```